Cargando…
Budget Impact of Introducing Linagliptin into Bosnia and Herzegovina Health Insurance Drug Reimbursement List in 2016-2018
INTRODUCTION: Diabetes is reaching epidemiological scales worldwide. Beside health implications diabetes bears significant financial impact on health systems. Different treatment options aiming to prevent diabetes complications are available. Dipeptidyl-peptidase-IV (DPP-4) inhibitors like linaglipt...
Autores principales: | Catic, Tarik, Lekic, Lana, Zah, Vlad, Tabakovic, Vedad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AVICENA, d.o.o., Sarajevo
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644199/ https://www.ncbi.nlm.nih.gov/pubmed/29109662 http://dx.doi.org/10.5455/msm.2017.29.176-181 |
Ejemplares similares
-
Pharmacoeconomic Analysis of Antiepileptic Reimbursement for Neuropathic Pain in Bosnia and Herzegovina – Budget Impact Analysis of Pregabalin
por: Catic, Tarik, et al.
Publicado: (2018) -
Pharmacists’ Attitudes and Role in Diabetes Management in Bosnia and Herzegovina
por: Catic, Tarik, et al.
Publicado: (2019) -
Patients Perception of Community Pharmacist in Bosnia and Herzegovina
por: Catic, Tarik, et al.
Publicado: (2013) -
Diabetology Care During COVID-19 Lockdown in Bosnia and Herzegovina – Diabetologists and Patients Perspective
por: Catic, Tarik, et al.
Publicado: (2020) -
Critical Appraisal of Reimbursement List in Bosnia and Herzegovina
por: Mujkic, Sabina, et al.
Publicado: (2017)